Identification of key candidate genes and pathways in endometrial cancer: Evidence from bioinformatics analysis

Lv,Sha; Xu,Xiaoxiao; Wu,Zhangying

doi:10.3892/ol.2019.11040

Identification of key candidate genes and pathways in endometrial cancer: Evidence from bioinformatics analysis

Authors:
- Sha Lv
- Xiaoxiao Xu
- Zhangying Wu
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550001, P.R. China
Published online on: November 1, 2019 https://doi.org/10.3892/ol.2019.11040
Pages: 6679-6689
Copyright: © Lv et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometrial cancer (EC) is the fourth most common cancer in women worldwide. Although researchers are exploring the biological processes of tumorigenesis and development of EC, the gene interactions and biological pathways of EC are not accurately verified. In the present study, bioinformatics methods were used to screen for key candidate genes and pathways that were associated with EC and to reveal the possible mechanisms at molecular level. Microarray datasets (GSE63678, GSE17025 and GSE3013) from the Gene Expression Omnibus database were downloaded and 118 differentially expressed genes (DEGs) were selected using a Venn diagram. Functional enrichment analyses were performed on the DEGs. A protein‑protein interaction network was constructed, including the module analysis. A total of 11 hub genes were identified from the DEGs, and functional enrichment analyses were performed to clarify their possible biological processes. A total of 118 DEGs were selected from three mRNA datasets. Functional enrichment demonstrated 27 downregulated genes that were primarily involved in the positive regulation of transcription from RNA polymerase II promoter, protein binding and the nucleus. A total of 91 upregulated DEGs were mainly associated with cell division, protein binding and the nucleus. Pathway analysis indicated that the downregulated DEGs were mainly enriched in pathways associated with cancer, and the upregulated DEGs were mainly enriched in the cell cycle. The 11 hub genes were primarily enriched in the cell cycle, oocyte meiosis, progesterone‑mediated oocyte maturation, the p53 signaling pathway and viral carcinogenesis. The integrated analysis showed that cyclin B1, ubiquitin conjugating enzyme E2 C and cell division cycle 20 may participate in the tumorigenesis, development and invasion of EC. In conclusion, the hub genes and pathways identified in the present study contributed to the understanding of carcinogenesis and progression of EC at the mechanistic and molecular‑biological level. As candidate targets for the diagnosis and treatment of EC, these genes deserve further investigation.

View Figures

View References

1	Eritja N, Yeramian A, Chen BJ, Llobet-Navas D, Ortega E, Colas E, Abal M, Dolcet X, Reventos J and Matias-Guiu X: Endometrial carcinoma: Specific targeted pathways. Adv Exp Med Biol. 943:149–207. 2017. View Article : Google Scholar : PubMed/NCBI
2	Patni R: Endometrial carcinoma: Evolution and overviewCurrent Concepts in Endometrial Cancer. Singapore: Springer; pp. 1–9. 2017, View Article : Google Scholar
3	Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
4	Tran AQ and Gehrig P: Recent advances in endometrial cancer. F1000Res. 6:812017. View Article : Google Scholar : PubMed/NCBI
5	Sheets SSF: Endometrial cancer. Surveillance, Epidemiology, and End Results Program. seer. cancer. gov. 2015.
6	Lax SF, Kendall B, Tashiro H, Slebos RJ and Ellenson L: The frequency of p53, k-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic pathways. Cancer. 88:814–24. 2000. View Article : Google Scholar : PubMed/NCBI
7	Feng ZZ, Chen WJ, Yang ZR, Lu ZG and Cai ZG: Expression of PTTG1 and PTEN in endometrial carcinoma: Correlation with tumorigenesis and progression. Med Oncol. 29:304–310. 2012. View Article : Google Scholar : PubMed/NCBI
8	Basil JB, Goodfellow PJ, Rader JS, Mutch DG and Herzog TJ: Clinical significance of microsatellite instability in endometrial carcinoma. Cancer. 89:1758–1764. 2000. View Article : Google Scholar : PubMed/NCBI
9	Hecht JL and Mutter GL: Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 24:4783–4791. 2006. View Article : Google Scholar : PubMed/NCBI
10	Clough E and Barrett T: The gene expression omnibus database//Statistical GenomicsNew York: Humana Press; pp. 93–110. 2106
11	Pappa KI, Polyzos A, Jacob-Hirsch J, Amariglio N, Vlachos GD, Loutradis D and Anagnou NP: Profiling of discrete gynecological cancers reveals novel transcriptional modules and common features shared by other cancer types and embryonic stem cells. PLoS One. 10:e01422292015. View Article : Google Scholar : PubMed/NCBI
12	Day RS, McDade KK, Chandran UR, Lisovich A, Conrads TP, Hood BL, Kolli VK, Kirchner D, Litzi T and Maxwell GL: Identifier mapping performance for integrating transcriptomics and proteomics experimental results. BMC Bioinformatics. 12:2132011. View Article : Google Scholar : PubMed/NCBI
13	Wu H, Chen Y, Liang J, Shi B, Wu G, Zhang Y, Wang Y, Wang D, Li R, Yi X, et al: Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature. 438:981–987. 2005. View Article : Google Scholar : PubMed/NCBI
14	Huang DW, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
15	Kanehisa M: The KEGG database//‘In Silico'Simulation of Biological Processes: Novartis Foundation Symposium 247. Chichester, UK, John Wiley & Sons, Ltd,. 247:91–103. 2002.
16	Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, et al: The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 32((Database Issue)): D258–D261. 2004.PubMed/NCBI
17	Ashburner M, Ball CA, Blake JA, Botstein D, Butler HL, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
18	Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huertacepas J, Simonovic M, Roth A, Santos A, Tsafou K, et al: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43((Database Issue)): D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
19	Smoot ME, Ono K, Ruscheinski J, Wang P and Ideker T: Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar : PubMed/NCBI
20	Bandettini WP, Kellman P, Mancini C, Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY and Arai AE: MultiContrast delayed enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: A clinical validation study. J Cardiovasc Magn Reson. 14:832012. View Article : Google Scholar : PubMed/NCBI
21	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne AJ, Heuer ML, Larsson EG, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
22	Maere S, Heymans K and Kuiper M: BiNGO: A Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks. Bioinformatics. 21:3448–3449. 2005. View Article : Google Scholar : PubMed/NCBI
23	Goldman M, Craft B, Hastie M, Repečka K, Kamath A, McDade F, Rogers D, Brooks AN, Zhu J and Haussler D: The UCSC Xena Platform for cancer genomics data visualization and interpretation. BioRxiv. 3264702019.
24	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
25	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
26	Tomczak K, Czerwinska P and Wiznerowicz M: Review the cancer genome atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
27	Werner T: Bioinformatics applications for pathway analysis of microarray data. Curr Opin Biotechnol. 19:50–54. 2008. View Article : Google Scholar : PubMed/NCBI
28	Moreau Y, De Smet F, Thijs G, Marchal K and De Moor B: Functional bioinformatics of microarray data: From expression to regulation. Proceedings IEEE. 90:1722–1743. 2002. View Article : Google Scholar
29	Ye Q, Lei L and Aili AX: Identification of potential targets for ovarian cancer treatment by systematic bioinformatics analysis. Eur J Gynaecol Oncol. 36:283–289. 2015.PubMed/NCBI
30	Ai Z, Wang J, Xu Y and Teng Y: Bioinformatics analysis reveals potential candidate drugs for cervical cancer. J Obstet Gynaecol Res. 39:1052–1058. 2013. View Article : Google Scholar : PubMed/NCBI
31	Tejera E, Bernardes J and Rebelo I: Preeclampsia: A bioinformatics approach through protein-protein interaction networks analysis. BMC Syst Biol. 6:972012. View Article : Google Scholar : PubMed/NCBI
32	Huang V, Zheng J, Qi Z, Wang J, Place RF, Yu J, Li H and Li LC: Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells. PLoS Genet. 9:e10038212013. View Article : Google Scholar : PubMed/NCBI
33	Lacey JV, Potischman N, Madigan MP, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lurain JR, Fillmore CM, et al: Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: Results from a U.S. case-control study. Cancer Epidemiol Biomarkers Prev. 13:607–612. 2004.PubMed/NCBI
34	Suman S and Mishra A: Network analysis revealed aurora kinase dysregulation in five gynecological types of cancer. Oncol Lett. 15:1125–1132. 2018.PubMed/NCBI
35	Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR and Boyd J: Gene expression profiling of tamoxifen-associated uterine cancers: Evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol. 92:719–725. 2004. View Article : Google Scholar : PubMed/NCBI
36	Krause K, Wasner M, Reinhard W, Haugwitz U, Dohna CL, Mössner J and Engeland K: The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res. 28:4410–4418. 2000. View Article : Google Scholar : PubMed/NCBI
37	Agostino SD, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G and Piaggio G: Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell. 10:191–202. 2006. View Article : Google Scholar : PubMed/NCBI
38	Alam SK, Yadav VK, Bajaj S, Datta A, Dutta SK, Bhattacharyya M, Bhattacharya S, Debnath S, Roy S, Boardman LA, et al: DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53. Cell Death Differ. 23:707–722. 2016. View Article : Google Scholar : PubMed/NCBI
39	Sisovsky V, Lasabova Z, Straka L, Telkova M, Rychly B, Minarik G, Gemzova K, Petrovic R, Szemes T, Turna J, et al: Tumour suppressor gene and protein TP53/P53 in normal endometrium and endometrial carcinoma. Pathology. 46 (Suppl 2):S912014. View Article : Google Scholar
40	Cai H, Xiang Y, Qu S, Long J, Cai Q, Gao J, Zheng W and Shu XO: Association of genetic polymorphisms in cell-cycle control genes and susceptibility to endometrial cancer among Chinese women. Am J Epidemiol. 173:1263–1271. 2011. View Article : Google Scholar : PubMed/NCBI
41	Nicolau-Neto P, Palumbo A, De Martino M, Esposito F, de Almeida Simão T, Fusco A, Nasciutti LE, Meireles Da Costa N and Ribeiro Pinto LF: UBE2C is a transcriptional target of the cell cycle regulator FOXM1. Genes. 9(pii): E1882018. View Article : Google Scholar : PubMed/NCBI
42	Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J, Chen Z, Chen H, Clinton SK, Chan KK and Wang Q: CCI-779 inhibits cell-cycle G2/M progression and invasion of castration resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer Res. 71:4866–4876. 2011. View Article : Google Scholar : PubMed/NCBI
43	Shen Z, Jiang X, Zeng C, Zheng S, Luo B, Zeng Y, Ding R, Jiang H, He Q, Guo J and Jie W: High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC Cancer. 13:1922013. View Article : Google Scholar : PubMed/NCBI
44	Fujita T, Ikeda H, Taira N, Hatoh S, Naito M and Doihara H: Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer. 9:872009. View Article : Google Scholar : PubMed/NCBI
45	Guo L, Ding Z, Huang N, Huang Z, Zhang N and Xia Z: Forkhead Box M1 positively regulates UBE2C and protects glioma cells from autophagic death. Cell Cycle. 16:1705–1718. 2017. View Article : Google Scholar : PubMed/NCBI
46	Bajaj S, Alam SK, Roy KS, Datta A, Nath S and Roychoudury S: E2 Ubiquitin-conjugating Enzyme, UBE2C Gene, is reciprocally regulated by Wild-type and Gain-of-Function Mutant p53. J Biol Chem. 291:14231–14247. 2016. View Article : Google Scholar : PubMed/NCBI
47	Takahashi Y, Ishii Y, Nishida Y, Ikarashi M, Nagata T, Nakamura T, Yamamori S and Asai S: Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH. Cancer Genet Cytogenet. 168:30–35. 2006. View Article : Google Scholar : PubMed/NCBI
48	Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, et al: Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 18:666–677. 2012. View Article : Google Scholar : PubMed/NCBI
49	Sakai N, Kajiyama Y, Iwanuma Y, Tomita N, Amano T, Isayama F, Ouchi K and Tsurumaru M: Study of abnormal chromosome regions in esophageal squamous cell carcinoma by comparative genomic hybridization: Relationship of lymph node metastasis and distant metastasis to selected abnormal regions. Dis Esophagus. 23:415–421. 2010.PubMed/NCBI
50	Harper JW, Burton JL and Solomon MJ: The anaphase-promoting complex: It's not just for mitosis any more. Genes Dev. 16:2179–2206. 2002. View Article : Google Scholar : PubMed/NCBI
51	Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K and Gabrielson E: Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res. 12:405–410. 2006. View Article : Google Scholar : PubMed/NCBI
52	Gayyed MF, Elmaqsoud NM, Tawfiek ER, El Gelany SA and Rahman MF: A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: Its correlation with tumor grade and stage. Tumor Biol. 37:749–762. 2016. View Article : Google Scholar
53	Liu L, Chen F, Xiu A, Du B, Ai H and Xie W: Identification of key candidate genes and pathways in endometrial cancer by integrated bioinformatical analysis. Asian Pac J Cancer Prev. 19:969–975. 2018.PubMed/NCBI